Agree with your view @Eagle0
We need to keep in mind that NEU and Acadia both sit on a joint steering committee regarding Daybue and this 2591 specific condition for two indications - Rett Syndrome & Fragile X. The condition comes into play if Acadia decides to progress Trofinetide for the potential treatment of another syndrome which Neuren more be consider 2591 for.
If 2591 is proven to be superior to Trofinetide (2566) in both safety (with less side effects) and efficacy, then why would Acadia proceed down a path with Trofinetide (2566) for another syndrome in which Neuren has already commenced work on.
It would be in both companies interests that Acadia seeks further 2591 licensing agreements with Neuren for any other particular non-competing syndrome indications that it has an interest in and for which Neuren itself is not considering.
Agree with your view @Eagle0We need to keep in mind that NEU and...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.96 |
Change
-0.170(1.12%) |
Mkt cap ! $1.956B | |||
| Open | High | Low | Value | Volume |
| $15.06 | $15.37 | $14.95 | $5.553M | 367.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1400 | $14.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 8746 | 3 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |